UBS Group
IMMX icon

UBS Group’s Immix Biopharma IMMX Stock Holding History

UBS Group’s Portfolio IMMX Stock Details IMMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$700K Buy
76,832
+18,233
+31% +$134K ﹤0.01% 5825
2025
Q4 		$306K Buy
58,599
+56,659
+2,921% +$233K ﹤0.01% 6352
2025
Q3 		$4.05K Sell
1,940
-12,032
-86% -$28.9K ﹤0.01% 8980
2025
Q2 		$28.9K Buy
13,972
+3,851
+38% +$7.75K ﹤0.01% 8188
2025
Q1 		$17K Sell
10,121
-4,087
-29% -$7.71K ﹤0.01% 8335
2024
Q4 		$31.3K Buy
14,208
+8,062
+131% +$14.7K ﹤0.01% 7573
2024
Q3 		$9.16K Buy
6,146
+2,992
+95% +$6.02K ﹤0.01% 7800
2024
Q2 		$6.25K Sell
3,154
-2,104
-40% -$4.83K ﹤0.01% 7935
2024
Q1 		$16.1K Buy
5,258
+2,630
+100% +$10.2K ﹤0.01% 7017
2023
Q4 		$18.2K Buy
+2,628
New +$11.9K ﹤0.01% 7162
2023
Q2 		– Sell
-2,301
Closed -$4.19K – 9231
2023
Q1 		$4.19K Sell
2,301
-2,386
-51% -$5.27K ﹤0.01% 8222
2022
Q4 		$10.7K Sell
4,687
-7,317
-61% -$9.75K ﹤0.01% 8473
2022
Q3 		$16K Buy
12,004
+7,667
+177% +$16.8K ﹤0.01% 7689
2022
Q2 		$11K Buy
+4,337
New +$8.47K ﹤0.01% 7811
2022
Q1 		– Sell
-32,649
Closed -$116K – 10539
2021
Q4 		$116K Buy
+32,649
New +$112K ﹤0.01% 6172

Other funds holding IMMX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return

UBS Group's IMMX Position: Q1 2026 in Review

UBS Group increased its Immix Biopharma (IMMX) stake by 31% in Q1 2026, buying an estimated $134K and bringing the position to 76,832 shares worth $700K. The position accounts for ﹤0.01% of the portfolio, ranked #5825.

UBS Group first reported a position in IMMX in Q4 2021 and has held it in 15 quarters since. 77 funds tracked by Wall St. Rank hold IMMX as of Q1 2026.

  • UBS Group held 76,832 shares of Immix Biopharma worth $700K as of Q1 2026.
  • UBS Group bought 18,233 Immix Biopharma shares in Q1 2026, an estimated $134K.
  • Immix Biopharma made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #5825 holding.
  • UBS Group first reported a position in Immix Biopharma in Q4 2021 and has held it in 15 quarters since.
  • 77 funds tracked by Wall St. Rank held Immix Biopharma as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.